Directory
Portfolio companies.
21,000+ PE-backed.
Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.
Active deals
6
currently held
Exits tracked
3
hand-checked
Sectors covered
1
across the portfolio
Countries covered
6
from every market
9 companies matching
| Company | Sector | Geo | Investor | Entry | Status | |
|---|---|---|---|---|---|---|
Primo Group MED I | Consumer Health | ARCHIMED | 2015 | Exited 2024 | ||
Fytexia MED I | Consumer Health | ARCHIMED | 2016 | Exited 2023 | ||
Natural Origins MED I | Consumer Health | ARCHIMED | 2016 | Exited 2017 | ||
Jeisys MED Rise | Consumer Health | South Korea | ARCHIMED | 2023 | Active | |
Prollenium Direct investment by Peugeot Invest | Consumer Health | Canada | Peugeot Invest | 2021 | Active | |
DermaPharm MED III | Consumer Health | ARCHIMED | 2025 | Active | ||
WiQo MED Platform II | Consumer Health | ARCHIMED | 2023 | Active | ||
Cellese MED Rise | Consumer Health | ARCHIMED | 2024 | Active | ||
Groupe Laboratoire Rivadis MED Rise | Consumer Health | ARCHIMED | 2025 | Active |
Primo Group
MED I
Sector
Consumer Health
InvestorARCHIMED
Entry
2015
Hold
9yr
Exit
2024
Fytexia
MED I
Sector
Consumer Health
InvestorARCHIMED
Entry
2016
Hold
7yr
Exit
2023
Natural Origins
MED I
Sector
Consumer Health
InvestorARCHIMED
Entry
2016
Hold
1yr
Exit
2017
Jeisys
MED Rise
South Korea
Sector
Consumer Health
InvestorARCHIMED
Entry
2023
Hold
3yr
Owners
2
Prollenium
Direct investment by Peugeot Invest
Canada
Sector
Consumer Health
InvestorPeugeot Invest
Entry
2021
Hold
5yr
Owners
2
DermaPharm
MED III
Sector
Consumer Health
InvestorARCHIMED
Entry
2025
Hold
1yr
WiQo
MED Platform II
Sector
Consumer Health
InvestorARCHIMED
Entry
2023
Hold
3yr
Cellese
MED Rise
Sector
Consumer Health
InvestorARCHIMED
Entry
2024
Hold
2yr
Groupe Laboratoire Rivadis
MED Rise
Sector
Consumer Health
InvestorARCHIMED
Entry
2025
Hold
1yr